Clinical Trial Update: Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults [Phase 3]

View source ↗

Summary

Open-label, single-arm Phase 3 study evaluating MYOBLOC for troublesome sialorrhea in adults; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sialorrhea

Drugs mentioned

• MYOBLOC (rimabotulinumtoxinB)

Snippet

Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC | Conditions: Sialorrhea | Phase 3 | Status: COMPLETED | Results posted: 2019-11-04